274 related articles for article (PubMed ID: 35689434)
1. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
[TBL] [Abstract][Full Text] [Related]
5. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
6. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
[TBL] [Abstract][Full Text] [Related]
9. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Cárdenas V; Le Gars M; Truyers C; Ruiz-Guiñazú J; Struyf F; Colfer A; Bonten M; Borobia A; Reisinger EC; Kamerling IMC; Douoguih M; Sadoff J
Vaccine; 2024 Jun; 42(16):3536-3546. PubMed ID: 38705804
[TBL] [Abstract][Full Text] [Related]
11. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
[TBL] [Abstract][Full Text] [Related]
12. A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.
He X; Aid M; Chandrashekar A; Yu J; McMahan K; Wegmann F; Jacob-Dolan C; Maron JS; Atyeo C; Wan H; Sellers D; Liu J; Lifton M; Gardner S; Bondzie EA; Barrett J; Ahmad K; Anioke T; Yalley-Ogunro J; Muench J; Goode A; Andersen H; Lewis MG; Alter G; Schuitemaker H; Zahn R; Barouch DH
Sci Transl Med; 2022 Mar; 14(638):eabm4996. PubMed ID: 35191769
[TBL] [Abstract][Full Text] [Related]
13. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
14. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
15. Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
Le Gars M; Sadoff J; Struyf F; Heerwegh D; Truyers C; Hendriks J; Gray G; Grinsztejn B; Goepfert PA; Schuitemaker H; Douoguih M
J Infect Dis; 2022 Sep; 226(6):979-982. PubMed ID: 35429381
[TBL] [Abstract][Full Text] [Related]
16. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H
N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
[TBL] [Abstract][Full Text] [Related]
18. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
[TBL] [Abstract][Full Text] [Related]
19. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
20. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.
Ukey R; Bruiners N; Mishra H; Mishra PK; McCloskey D; Onyuka A; Chen F; Pinter A; Weiskopf D; Sette A; Roy J; Gaur S; Gennaro ML
BMC Med; 2022 Jan; 20(1):32. PubMed ID: 35073931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
